Phase 4 open-label study of mRNA COVID-19 vaccination (43 analysed): prior anti-SARS-CoV-2 monoclonal antibody recipients had lower day-140 neutralising antibody titres and fewer RBD-specific memory B cells; T-cell responses did not differ by prior mAb exposure.
RCTn = 43
Smith et al. Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-Elicited SARS-CoV-2 Immune Responses